Loading...
•
Mar 31
Glaukos Q1 2025 Earnings Report
Reported financial results for the first quarter ended March 31, 2025, including record net sales and improved operating loss compared to the prior year period.
Key Takeaways
Glaukos reported a strong start to 2025 with record net sales of $106.7 million in the first quarter, representing a 25% increase year-over-year. The company's operating loss improved significantly to $20.7 million from $39.1 million in the same period last year. Glaucoma sales were a key driver of growth, increasing 31% year-over-year.
Record net sales of $106.7 million in Q1 2025, up 25% year-over-year.
Glaucoma net sales reached a record $88.1 million, a 31% increase from the prior year.
U.S. Glaucoma net sales grew 41% year-over-year to $59.1 million.
Operating loss improved to $20.7 million in Q1 2025 compared to a loss of $39.1 million in Q1 2024.
Glaukos
Glaukos
Glaukos Revenue by Segment
Glaukos Revenue by Geographic Location
Revenue by Segment
Glaucoma Revenue
CapyFin.comRevenue by Geographic Location
U.S. Glaucoma Revenue
CapyFin.comInternational Glaucoma Revenue
CapyFin.com Forward Guidance
Glaukos reaffirmed its full-year 2025 net sales guidance.
Positive Outlook
- Reaffirmed 2025 net sales guidance of $475 million to $485 million.
- Strong start to the year reflecting sustained growth acceleration.
- Successful global execution of key strategic plans.
- Continued advancement of robust pipeline of novel, dropless platform technologies.
- iDose® TR commercial launch activities progressing.
Challenges Ahead
- Guidance range is broad, reflecting potential uncertainties.
- Subject to general macroeconomic conditions, including foreign currency fluctuations.
- Ability to successfully commercialize new products like iDose TR is a factor.
- Dependence on a limited number of third-party suppliers poses a risk.
- Securing or maintaining adequate coverage or reimbursement by third-party payors is crucial.